IDEAS home Printed from https://ideas.repec.org/a/sae/envira/v30y1998i10p1723-1741.html
   My bibliography  Save this article

The Indianapolis ‘Fortune 500’: Lilly and Regional Renaissance

Author

Listed:
  • S M Walcott

    (Department of Geography, Georgia State University, Atlanta, GA 30303-3083, USA)

Abstract

The reasons for and consequences of the location of a flourishing industrial anomaly ouside the predominant region of concentration is of continuing geographic interest. This paper is an examination of both structural and agency factors for the historical establishment and consistent success of pharmaceutical giant Eli Lilly and Company. Along with its recent medical device spinoff, Lilly is the only ‘Fortune 500’ firm in Indianapolis, and one of few outside the Mid-Atlantic states cluster. Industry-locational exceptionalism is sustained by a cross-sectoral concentration of related manufacturing and service companies to create a health ensemble. A consciously constructed local metropolitan and state sociopolitical niche further nurtures industry-specific and mutually beneficial growth. Theories on agglomeration-sustaining patterns are considered in light of this empirical study.

Suggested Citation

  • S M Walcott, 1998. "The Indianapolis ‘Fortune 500’: Lilly and Regional Renaissance," Environment and Planning A, , vol. 30(10), pages 1723-1741, October.
    • Handle: RePEc:sae:envira:v:30:y:1998:i:10:p:1723-1741
    DOI: 10.1068/a301723
    as

    Download full text from publisher

    File URL: https://journals.sagepub.com/doi/10.1068/a301723
    Download Restriction: no
    File URL: https://libkey.io/10.1068/a301723?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Feldman, Maryann & Schreuder, Yda, 1996. "Initial Advantage: The Origins of the Geographic Concentration of the Pharmaceutical Industry in the Mid-Atlantic Region," Industrial and Corporate Change, Oxford University Press and the Associazione ICC, vol. 5(3), pages 839-862.
    2. Gambardella,Alfonso, 1995. "Science and Innovation," Cambridge Books, Cambridge University Press, number 9780521451185, October.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Jeffrey Furman & Margaret K. Kyle & Alain Cockburn & Rebecca M. Henderson, 2005. "Public & Private Spillovers: Location and the Productivity of Pharmaceutical Research," Annals of Economics and Statistics, GENES, issue 79-80, pages 165-188.
    2. Christian Zeller, 2010. "The Pharma-biotech Complex and Interconnected Regional Innovation Arenas," Urban Studies, Urban Studies Journal Limited, vol. 47(13), pages 2867-2894, November.
    3. Lee Branstetter & Kwon Hyeog Ug, 2004. "The Restructuring Of Japanese Research And Development: The Increasing Impact Of Science On Japanese R&D," Discussion papers 04021, Research Institute of Economy, Trade and Industry (RIETI).
    4. Scherer, F. M., 2007. "Pharmaceutical Innovation," Working Paper Series rwp07-004, Harvard University, John F. Kennedy School of Government.
    5. Stephan, Michael, 2013. "Theorien der Industrieevolution," Discussion Papers on Strategy and Innovation 13-03, Philipps-University Marburg, Department of Technology and Innovation Management (TIM).
    6. Lionel Nesta & Pier Paolo Saviotti, 2005. "Coherence Of The Knowledge Base And The Firm'S Innovative Performance: Evidence From The U.S. Pharmaceutical Industry," Journal of Industrial Economics, Wiley Blackwell, vol. 53(1), pages 123-142, March.
    7. Silvia Galli, 2006. "Patents and Research Tools in a Schumpeterian Growth Model with Sequential Innovation," Rivista di Politica Economica, SIPI Spa, vol. 96(6), pages 63-104, November-.
    8. Maureen McKelvey & Bastian Rake, 2012. "Research Network Position and Innovative Performance: Evidence from the Pharmaceutical Industry," Jena Economics Research Papers 2012-021, Friedrich-Schiller-University Jena.
    9. Gambardella, Alfonso & Orsenigo, Luigi & Pammolli, Fabio, 2000. "Global Competitiveness in Pharmaceuticals: A European Perspective," MPRA Paper 15965, University Library of Munich, Germany.
    10. Christian Garavaglia & Franco Malerba & Luigi Orsenigo & Michele Pezzoni, 2013. "Technological Regimes and Demand Structure in the Evolution of the Pharmaceutical Industry," Economic Complexity and Evolution, in: Andreas Pyka & Esben Sloth Andersen (ed.), Long Term Economic Development, edition 127, pages 61-94, Springer.
    11. Bruce Rasmussen, 2010. "Innovation and Commercialisation in the Biopharmaceutical Industry," Books, Edward Elgar Publishing, number 13680.
    12. Novelli, Elena, 2015. "An examination of the antecedents and implications of patent scope," Research Policy, Elsevier, vol. 44(2), pages 493-507.
    13. Bastian Rake, 2017. "Determinants of pharmaceutical innovation: the role of technological opportunities revisited," Journal of Evolutionary Economics, Springer, vol. 27(4), pages 691-727, September.
    14. Furman, Jeffrey L. & MacGarvie, Megan J., 2007. "Academic science and the birth of industrial research laboratories in the U.S. pharmaceutical industry," Journal of Economic Behavior & Organization, Elsevier, vol. 63(4), pages 756-776, August.
    15. Ashish Arora & Sharon Belenzon & Andrea Patacconi & Jungkyu Suh, 2020. "The Changing Structure of American Innovation: Some Cautionary Remarks for Economic Growth," Innovation Policy and the Economy, University of Chicago Press, vol. 20(1), pages 39-93.
    16. Arnold, Denis G. & Amato, Louis H. & Troyer, Jennifer L. & Stewart, Oscar Jerome, 2022. "Innovation and misconduct in the pharmaceutical industry," Journal of Business Research, Elsevier, vol. 144(C), pages 1052-1063.
    17. Mark Lorenzen & Bo Carlsson, 2014. "Maryann Feldman: Recipient of the 2013 Global Award for Entrepreneurship Research," Small Business Economics, Springer, vol. 43(1), pages 1-8, June.
    18. Iain M. Cockburn & Rebecca M. Henderson, 2001. "Publicly Funded Science and the Productivity of the Pharmaceutical Industry," NBER Chapters, in: Innovation Policy and the Economy, Volume 1, pages 1-34, National Bureau of Economic Research, Inc.
    19. Heide Fier & Andreas Pyka, 2014. "Against the one-way-street: analyzing knowledge transfer from industry to science," The Journal of Technology Transfer, Springer, vol. 39(2), pages 219-246, April.
    20. Ronnie Ramlogan & Davide Consoli, 2014. "Dynamics of collaborative research medicine: the case of glaucoma," The Journal of Technology Transfer, Springer, vol. 39(4), pages 544-566, August.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:sae:envira:v:30:y:1998:i:10:p:1723-1741. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: SAGE Publications (email available below). General contact details of provider: .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.